EUCTR2008-000498-40-ES进行中（未招募）1 期
Estudio aleatorizado , doble-ciego, controlado con placebo, multicéntrico, de fase III, para evaluar la terapia adyuvante con RAD001 frente a placebo, en pacientes con linfoma difuso de células grandes B (LDCGB) de elevado riesgo que hayan alcanzado una respuesta completa tras una primera línea de quimioterapia con rituximab.
ovartis Farmacéutica S.A.0 个研究点目标入组 915 人开始时间: 2010年11月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 915
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with previous histologically-confirmed Stage III-IV (or Stage II bulky disease defined as any tumor mass more than 10 cm in largest diameter), at time of original diagnosis, diffuse large B cell lymphoma (pathology report based on original tumor tissue/lymph node is acceptable for meeting inclusion criteria, but tumor tissue
- •(slides/block) must be available to be sent for central pathology to confirm diagnosis).
- •2. Patients defined as poor risk with IPI of 3, 4, or 5 at time of original diagnosis.
- •3. Patients age ? 18 years old.
- •4. Patients must have achieved complete remission (CR) based on the revised IWRC
- •(Cheson et al 2007) following first line R-CHOP treatment. Radiation therapy in combination with R-CHOP is acceptable if the radiation therapy ended by the time of RCHOP completion. Complete remission from R-CHOP must be confirmed by clinical and radiologic evaluation along with bone marrow confirmation (if bone marrow was involved by lymphoma before the R-CHOP treatment). Local pathology report on the bone marrow biopsy is acceptable. If bone marrow was not involved by lymphoma before R-CHOP treatment, then bone marrow confirmation after R-CHOP is not required.
- •5. Patients who received a minimum 6 cycles of R-CHOP treatment and maximum 8 cycles of R-CHOP treatment. Any variation of CHOP (R-CHOP-14, R-CHOP-21) is acceptable. Liposomal doxorubicin is acceptable.
- •6. Patients? last treatment with R-CHOP must be 6 to 12 weeks prior to start of study drug.
- •7. Patients with ECOG performance status (PS) 0, 1, or 2.
- •8. Patients willing to provide a portion of his/her tumor tissue from original diagnosis or lymph node to confirm diagnosis.
- •9. The following laboratory values obtained ? 21 days prior to start of study drug:
- •? Absolute neutrophil count ? 1000/mm3 (or 1.0 GI/L, SI units)
- •? Platelet count ? 100,000/mm3 (or 100 GI/L, SI units)
- •? Hemoglobin ? 9 g/dL (can be achieved by transfusion)
- •? Total bilirubin ? 2 x ULN (if >2 x ULN direct bilirubin is required and should be ?1.5
- •? AST ? 3 x ULN (? 5 x ULN if liver involvement is present)
- •? Serum creatinine ? 2 x ULN
- •10. Women of childbearing potential must have had a negative serum pregnancy test 7 days prior to the start of study drug.
- •11. Patients who give a written informed consent obtained according to local guidelines.
- •12. Patients capable of swallowing intact study medication tablets and following directions regarding taking study drug, or have a daily caregiver who will be responsible for administering study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with evidence of disease according to the revised IWRC (Cheson et al 2007) after completion of the first-line R-CHOP treatment, prior to study entry.
- •2. Patients receiving ongoing radiation therapy or who received radiation therapy to the residual tumor masses after R-CHOP.
- •3. Patients who have previously received systemic mTOR inhibitor (sirolimus, temsirolimus, everolimus, etc).
- •4. Patients with evidence of current central nervous system (CNS) involvement. Patients who have only had prophylactic intrathecal or intravenous chemotherapy against CNS disease are eligible.
- •5. Patients with transformed follicular lymphoma.
- •6. Patients who received ibritumomab tiuxetan (Zevalin®), in order, to avoid potential delayed kidney toxicities.
- •7. Patients who had myelosuppressive chemotherapy or biologic therapy < 3 weeks.
- •8. Patients receiving chronic systemic immunosuppressive agents. Inhaled and topical
- •steroids are acceptable. Patients may be receiving stable (not increased within the last month) chronic doses of corticosteroids with a maximum dose of 20 mg of prednisone or 10 mg of dexamethasone per day, if they are being given for disorders other than lymphoma such as rheumatoid arthritis, polymyalgia rheumatica or adrenal insufficiency or asthma.
- •9. Patients with active, bleeding diathesis.
- •10. Patients with a known history of HIV seropositivity, chronic hepatitis, or other active viral infections.
- •11. Patients with known hypersensitivity to RAD001 (everolimus) or other rapamycins
- •(sirolimus, temsirolimus) or to any of the excipients.
- •12. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
- •? unstable angina pectoris, symptomatic congestive heart failure (NYHA II, III, IV),
- •myocardial infarction ? 6 months prior to first study drug, serious uncontrolled cardiac arrhythmia, cerebrovascular accidents ? 6 months before study drug start
- •? severely impaired lung function as defined as spirometry and DLCO that is 50% of
- •the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
- •? poorly controlled diabetes as defined by fasting serum glucose >2.0 x ULN
- •? any active (acute or chronic) or uncontrolled infection/disorders that impair the ability to evaluate the patient or for the patient to complete the study
- •? nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by this study drug, such as severe hypertension that is not controlled with medical management and thyroid abnormalities whose thyroid function cannot be maintained in the normal range by medication
- •? liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis or chronic persistent hepatitis.
- •13. Patients who have a history of another primary malignancy ? 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of uterine cervix.
- •14. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Oral contraceptives are not acceptable.
- •15. Patients who are using other investigational agents or who had received investigational drugs ? 4 weeks prior to study drug start.
- •16. Patients unwilling to or unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
不适用
Estudio aleatorizado, doble-ciego, controlado con placebo, de búsqueda de dosis, para evaluar la eficacia y seguridad de SAR153191 en pacientes con espondilitis anquilosante_______________________________________________A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - ALIGEspondilitis anquilosante___________________________Ankylosing SpondylitisMedDRA version: 12.0Level: LLTClassification code 10002556Term: Ankylosing spondylitisEUCTR2009-016068-35-ESSanofi-aventis Recherche & Développement300
进行中（未招募）
1 期
Estudio aleatorizado, doble-ciego, controlado con placebo, de grupos paralelos, de definición de dosis, para investigar la eficacia mediante RM y la seguridad de la administración de firategrast (150 - 1.200 mg, dos veces al día), durante seis meses, en sujetos con esclerosis múltiple remitente-recurrenteEUCTR2006-002633-20-ESGlaxoSmithKline S.A
进行中（未招募）
1 期
Estudio aleatorizado, doble-ciego, controlado con placebo, multicéntrico, de dos partes, de búsqueda de dosis y confirmatorio, con un diseño operacionalmente adaptativo que evalúa la eficacia y seguridad de SAR153191 junto con metotrexato (MTX), en pacientes con artritis reumatoide activa con respuesta inadecuadada a la terapia con metotrexato__________________________________________________A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of methotrexate (MTX) in patients with active rheumatoid arthritis who are inadequate responders to MTX therapy - MOBILITYArtritis Reumatoide_____________________________________Rheumatoid ArthritisMedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2009-016266-90-ESSanofi-aventis Recherche & Développement1,675
进行中（未招募）
1 期
Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 14 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de Nerispirdina 50 mg, 100 mg y 200 mg en pacientes con Esclerosis Múltiple___________________________________________________________________A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple SclerosisEsclerosis Múltiple______________Multiple SclerosisMedDRA version: 11.0Level: LLTClassification code 10028245Term: <Manually entered code. Term in E.1.1>EUCTR2008-001999-67-ESsanofi-aventis Recherche & Développement368
进行中（未招募）
不适用
Estudio aleatorizado, doble ciego, controlado con placebo, de la seguridad y eficacia de Xyrem® (oxibato sódico) en sujetos con fibromialgia(A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® (sodium oxybate) in Subjects with Fibromyalgia)fibromialgiaMedDRA version: 8.1Level: LLTClassification code 10048439Term: FibromyalgiaEUCTR2006-006075-20-ESJazz Pharmaceuticals, Inc.525